BidaskClub cut shares of CytomX Therapeutics (NASDAQ:CTMX) from a buy rating to a hold rating in a report released on Thursday morning.
CTMX has been the topic of a number of other reports. Wedbush initiated coverage on shares of CytomX Therapeutics in a research report on Thursday, September 7th. They set an outperform rating and a $26.00 price objective on the stock. Nomura boosted their price objective on shares of CytomX Therapeutics to $44.00 and gave the company a buy rating in a research report on Wednesday, October 4th. ValuEngine downgraded shares of CytomX Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Zacks Investment Research downgraded shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Friday, November 10th. Finally, Jefferies Group set a $25.00 price objective on shares of CytomX Therapeutics and gave the company a buy rating in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. CytomX Therapeutics currently has a consensus rating of Hold and an average price target of $31.88.
CytomX Therapeutics (CTMX) opened at $20.56 on Thursday. CytomX Therapeutics has a 1 year low of $10.40 and a 1 year high of $24.67.
Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc boosted its holdings in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares in the last quarter. Macquarie Group Ltd. bought a new position in CytomX Therapeutics in the 3rd quarter worth about $107,000. Cubist Systematic Strategies LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth about $174,000. Goldman Sachs Group Inc. bought a new position in CytomX Therapeutics in the 1st quarter worth about $190,000. Finally, Voya Investment Management LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth about $203,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.
WARNING: “BidaskClub Lowers CytomX Therapeutics (CTMX) to Hold” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/12/10/bidaskclub-lowers-cytomx-therapeutics-ctmx-to-hold.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.